Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.

Abstract excerpt

Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clinical Trials as Topic
• Share to Enzyme Inhibitors
• Share to fms-Like Tyrosine Kinase 3